Want to inform investors similar to Therapiva about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Therapiva News
Oct 16, 2018
By Maggie Lynch Dr. Reddy’s Laboratory has decided to sell its API manufacturing plant to generics joint venture, Therapiva. Dr. Reddy’s decision to sell its active pharmaceutical ingredient (API) manufacturing plant follows the recent sale of the company’s US based manufacturing facility. The sale will include all related fixed assets, current assets, current liabilities and its employees. Dr. Reddy’s stated that the decision to divest its API manufacturing business unit is a step towards streamlining operations and optimizing costs. The company said that it will allow for a focus on manufacturing generic formulations. A spokesperson from Dr. Reddy’s told us that from this sale the company is optimistic about realizing meaningful benefits from this transaction. “However, we are not disclosing any specific financials related to anticipated cost savings,” said the spokesperson. The first sale to Neopharma was reported to be an attempt by Dr. Reddy’s to optimize global cost structures. In this sale, the company sold its antibiotics (penicillin) portfolio with the sale of its manufacturing site. The spokesperson told us that the two transactions are still unrelated despite being sold to the same buyer. Therapiva a joint venture between Omnicare drugs, a Neopharma subsidiary, and Laxai manufacturing. Copyright - Unless otherwise stated all contents of this web site are © 2018 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Therapiva Acquisitions
1 Acquisition
Therapiva acquired 1 company. Their latest acquisition was Dr. Reddys Laboratories - Hyderabad API Unit on October 15, 2018.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
10/15/2018 | Acquired Unit | 1 |
Date | 10/15/2018 |
|---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired Unit |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.